ESMO Guidelines: Real World Cases - Webinar Series: Bladder Cancer 2025

Description

This ESMO Clinical Practice Guidelines Webinar focused on bladder cancer and its application in a real-world case.

Bladder cancer is the 10th most common cancer worldwide, with more than 550,000 new cases and 200,000 deaths annually. Despite advances in diagnosis and treatment, the transition from localised disease to metastatic relapse presents significant challenges in clinical practice.

The European Society for Medical Oncology (ESMO) has updated its clinical practice guidelines to reflect advancements in the management of localised bladder cancer and strategies for addressing metastatic relapse. Considerations include novel diagnostic techniques, surgical interventions, and systemic therapies, including the introduction of immune checkpoint inhibitors and antibody-drug conjugates, underscoring the importance of personalised treatment plans.

Given the evolving therapeutic landscape and the uncertainties around the optimal use of new therapies, it is essential for healthcare professionals to stay informed about the latest evidence-based recommendations. This webinar focused on the 2024 ESMO guidelines provided a timely platform to disseminate critical information, discuss evolving treatment strategies, patient selection, practical applications, and address challenges in implementing these recommendations, ultimately enhancing patient outcomes in bladder cancer care.